- Complete Atrioventricular Block Secondary to Bortezomib Use in Multiple Myeloma
-
Lee WS, Kim DH, Shin SH, Woo SI, Kwan J, Park KS, Park SD, Yi HG, Jeon SH
- KMID: 1106457
- Yonsei Med J.
- 2011 Jan;52(1):196-198.
- doi: 10.3349/ymj.2011.52.1.196
Bortezomib is an inhibitor of 26S proteasome, which is an effective treatment for multiple myeloma. The common adverse effects of bortezomib are asthenic conditions, gastrointestinal disturbances, and peripheral neuropathy. Here... -
- CITED
-
- Close
- SHARE
-
- Close
- Acute Exacerbation of Chronic Hepatitis B During Thalidomide Therapy for Multiple Myeloma: A Case Report
-
Bang SM, Kim SS, Park SH, Ahn JY, Cho EK, Shin DB, Lee JH
- KMID: 1115232
- Korean J Intern Med.
- 2004 Sep;19(3):196-198.
We report a case of acute fatal exacerbation of chronic hepatitis B in a 50-year-old man with multiple myeloma being treated with thalidomide. The patient had a medical history of... -
- CITED
-
- Close
- SHARE
-
- Close
- Nonspecific Interstitial Pneumonitis after Bortezomib and Thalidomide Treatment in a Multiple Myeloma Patient
-
Kang W, Kim JS, Cho SH, Kim SK, Chang J, Park MS
- KMID: 1074999
- Yonsei Med J.
- 2010 May;51(3):448-450.
- doi: 10.3349/ymj.2010.51.3.448
Bortezomib, an inhibitor of 26S proteosome, is recently approved treatment option for multiple myeloma. Thalidomide, a drug with immunomodulating and antiangiogenic effects, has also shown promise as an effective treatment... -
- CITED
-
- Close
- SHARE
-
- Close
- Thalidomide Induced Nonspecific Interstitial Pneumonia in Patient with Relapsed Multiple Myeloma
-
Kang MH, Ju JH, Kim HG, Kang JH, Jeon KN, Kim HC, Lee GW
- KMID: 964727
- Korean J Intern Med.
- 2010 Dec;25(4):447-449.
- doi: 10.3904/kjim.2010.25.4.447
A 63-year-old female diagnosed with relapsed multiple myeloma visited our hospital complaining of a persistent cough. Since July 2006, she had been taking 100 mg thalidomide daily and gradually developed... -
- CITED
-
- Close
- SHARE
-
- Close
- A Combination of Melphalan, Prednisone, and 50 mg Thalidomide Treatment in Non-Transplant-Candidate Patients with Newly Diagnosed Multiple Myeloma
-
Chang HJ, Lee JH, Do YR, Bae SH, Lee JL, Nam SH, Yoon SS, Bang SM
- KMID: 1729242
- Korean J Intern Med.
- 2011 Dec;26(4):403-409.
- doi: 10.3904/kjim.2011.26.4.403
BACKGROUND/AIMS: The clinical efficacy and safety of a three-drug combination of melphalan, prednisone, and thalidomide were assessed in patients with multiple myeloma who were not candidates for high-dose therapy as... -
- CITED
-
- Close
- SHARE
-
- Close
- A Pilot Study of Bortezomib in Korean Patients with Relapsed or Refractory Myeloma
-
Lee KW, Yun T, Song EK, Na II, Shin H, Bang SM, Lee JH, Lee ST, Kim JH, Yoon SS, Lee JS, Park S, Kim BK, Kim NK
- KMID: 1712739
- J Korean Med Sci.
- 2005 Aug;20(4):598-602.
- doi: 10.3346/jkms.2005.20.4.598
Recent clinical trials showed that bortezomib, a novel proteasome inhibitor, had therapeutic activity in multiple myeloma. However, there was no data about the feasibility of bortezomib in Korean patients. We... -
- CITED
-
- Close
- SHARE
-
- Close
- Is the Low-Thalidomide Dose MPT Regimen Beneficial?
-
Min CK
- KMID: 1729241
- Korean J Intern Med.
- 2011 Dec;26(4):400-402.
- doi: 10.3904/kjim.2011.26.4.400
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Poor Outcomes for IgD Multiple Myeloma Patients Following High-Dose Melphalan and Autologous Stem Cell Transplantation: A Single Center Experience
-
Chong YP, Kim S, Ko OB, Koo JE, Lee D, Park SH, Park SJ, Lee D, Kim SW, Suh C
- KMID: 1783067
- J Korean Med Sci.
- 2008 Oct;23(5):819-824.
- doi: 10.3346/jkms.2008.23.5.819
Immunoglobulin (Ig) D multiple myeloma (MM) accounts for 2% of all MM cases and has been reported to be associated with poor prognosis compared with other MM subtypes. The aim... -
- CITED
-
- Close
- SHARE
-
- Close
- Early Response to Bortezomib Combined Chemotherapy Can Help Predict Survival in Patients with Multiple Myeloma Who Are Ineligible for Stem Cell Transplantation
-
Lee HS, Kim YS, Kim K, Kim JS, Kim HJ, Min CK, Suh C, Eom HS, Yoon SS, Lee JH, Kim MK, Kim SH, Bae SH, Mun YC, Jo DY, Chung JS, The Korean Multiple Myeloma Working Party (KMMWP)
- KMID: 2158005
- J Korean Med Sci.
- 2013 Jan;28(1):80-86.
- doi: 10.3346/jkms.2013.28.1.80
Novel agents to treat multiple myeloma (MM) have increased complete respone (CR) rates compared with conventional chemotherapy, and the quality of the response to treatment has been correlated with survival.... -
- CITED
-
- Close
- SHARE
-
- Close
